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Magnetic albumin nanospheres that incorporate doxo-
rubicin (M-DOX-BSA-NPs) were prepared previously by
our research group to develop magnetically responsive
drug carrier system. This nanocarrier was synthesized
as a drug delivery system for targeted chemotherapy.
In this work, cytotoxic effects of doxorubicin (DOX)-
loaded/unloaded or magnetic/non-magnetic nanoparti-
cles and free DOX against PC-3 cells and A549 cells
were determined with the MTT test and the results
were compared with each other. DOX-loaded magnetic
albumin nanospheres (M-DOX-BSA-NPs) were found
more cytotoxic than other formulations. The quantita-
tive data obtained from flow cytometry analysis further
verified the higher targeting and killing ability of M-
DOX-BSA-NPs than free DOX on both of the cancer
cell lines. Additionally, the results of cell cycle analysis
have showed that M-DOX-BSA-NPs affected G1 and
G2 phases. Finally, cell images were obtained using
spin-disk confocal microscopy, and cellular uptake of
M-DOX-BSA-NPs was visualized. The findings of this
study suggest that M-DOX-BSA-NPs represent a
potential doxorubicin delivery system for targeted drug
transport into prostate and lung cancer cells.
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In the last two decades, a number of nanoparticle-based
therapeutic and diagnostic agents have been developed
for the treatment of cancer (1). Nanoparticles made of
albumin, which is a plasma protein, offer several specific
advantages: they are non-toxic, non-antigenic, biodegrad-
able, easy to prepare, reproducible, and well tolerated (2).
There are human serum albumin-based particle formula-
tions on the market such as AlbunexTM and AbraxaneTM.
Doxorubicin (DOX) is the best known and most widely
used member of the anthracycline antibiotic group of anti-
cancer agents (3). DOX has a number of undesirable side-
effects such as nausea, vomiting, hair loss, cardiotoxicity,
and myelosuppression, which leads to a very narrow ther-
apeutic index (4). Its mode of action is complex and not
completely understood, but it is believed to interact with
cell DNA by intercalation and subsequent inhibition of bio-
synthesis (5).
Nanoparticles, using both passive and active targeting
strategies, can enhance the intracellular accumulation of
drugs in cancer cells while avoiding toxicity in normal cells
(6). Magnetic drug targeting ensures the concentration of
drugs at a defined target site with the aid of a magnetic
field. Typically, magnetic compound is injected through the
artery supplying the tumor tissue in the presence of an
external magnetic field with sufficient field strength and
gradient to retain the carrier at the target site (7). Ferrimag-
netic magnetite (Fe3O4) is suitable and biocompatible for
in vivo applications as cell homeostasis is well controlled
by iron uptake, excretion, and storage, and the iron
excess is efficiently cleared from the body (8).
The purpose of this study was to evaluate the in vitro cyto-
toxicity effect of doxorubicin-loaded magnetic albumin
nanospheres which were developed previously by our
research group (5), against prostate and lung cancer cell
lines. For this purpose, cell viability tests and apoptosis
rate analysis were carried out, and cell images were visual-
ized using optical and spin-disk confocal microscopy.
Methods and Materials
Materials
Bovine serum albumin (BSA) was purchased from Sigma-
Aldrich Chemical co. (St. Louis, MO, USA), glutaraldehyde
was obtained from Merck Chemical Co. (Darmstadt, Ger-
many), and doxorubicin (DOX) was supplied from Med-Ilac
(Istanbul, Turkey). All the other reagents were analytical
grade. For cell culture studies, Roswell Park Memorial Insti-
tute-1640 (RPMI-1640) growth medium, Dulbecco’s modi-
fied Eagle’s medium (DMEM) growth medium, fetal bovine
serum (FBS), and gentamicin sulfate were obtained from
Gibco, BRL (New York, NY, USA). Dimethyl sulfoxide
(DMSO), trypan blue dye, and MTT reagent were purchased
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from Sigma-Aldrich Chemical co. Phosphate-buffered sal-
ine (PBS) was supplied from Invitrogen (Carlsbad, CA,
USA). Annexin V apoptosis detection kit I was purchased
from BD Pharmingen (SanDiego, CA, USA). Absolute etha-
nol was purchased from AppliChem GmbH (Darmstadt,
Germany).
Preparation of doxorubicin-incorporated magnetic
albumin nanospheres
Doxorubicin-incorporated magnetic albumin nanospheres
(M-DOX-BSA-NPs) were developed according to the
method described in our previous study (5). Briefly, doxo-
rubicin, magnetite, and albumin were dissolved in water,
and then, ethanol was added dropwise under constant
shaking at room temperature. To cross-link and stabilize
the nanoparticles, glutaraldehyde was added to the mix-
ture. After 24-h reaction time, nanoparticles were purified
and washed with water by centrifugation. M-DOX-BSA-
NPs were characterized with dynamic light scattering
(DLS), atomic force microscopy (AFM), scanning electron
microscopy (SEM), vibrometric sample magnetometer
(VSM), and X-ray powder diffractometer (XRD). The
obtained nanospheres were freeze-dried and stored at
20 °C until their use.
Cell cultures
PC3 (human prostate cancer cell) and A549 (adenocarci-
nomic human alveolar basal epithelial cell) cell lines were
kindly provided from Biotechnology and Bioengineering
Research and Application Centre, Izmir Institute of Tech-
nology, Turkey. The prostate cancer cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 5% fetal bovine serum (FBS) and 1% genta-
micin sulfate, and lung cancer cells were grown in Roswell
Park Memorial Institute-1640 (RPMI-1640) growth medium
containing 10% fetal bovine serum (FBS) and 1% gentami-
cin sulfate at 37 °C in 5% CO2. Medium was refreshed
every 3 days. All nanoparticles were dissolved in DMSO,
and doxorubicin was dissolved in PBS before all the analy-
ses.
In vitro cytotoxicity assessments
The cytotoxicity of various concentrations of the albumin
nanoparticles (BSA-NPs), magnetic albumin nanoparticles
(M-BSA-NPs), DOX, DOX-incorporated BSA nanoparticles
(DOX-BSA-NPs), DOX-loaded magnetic BSA nanoparticles
(M-DOX-BSA-NPs) on cancer cells was determined using
the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoli-
um bromide) assay. MTT, a yellow tetrazole, is reduced to
purple formazan in living cell’s mitochondria (9). The result-
ing formazan crystals were dissolved in DMSO. The absor-
bance of this solution can be quantified at 570 nm
spectrophotometrically. This reduction only occurs if mito-
chondrial reductase enzymes are active; thus, conversion
is directly related to the number of viable cells.
MTT-based in vitro cytotoxicity assay was performed to
investigate and compare the effects of free DOX, DOX-
BSA-NPs, M-DOX-BSA-NPs, BSA-NPs, and M-BSA-NP
against PC3 and A549 cells according to the method
described by Yamada et al. (10). PC3 and A549 cells were
inoculated in 96-well plates at a density of 1 9 104 cells/
mL and incubated for 24 h. DOX, DOX-loaded and
unloaded nanocarriers that have a concentration range
between 0.02 and 50 lM (for DOX containing formulations
means DOX concentrations in the formulation) were added
to cells and incubated for 48 h. Thereafter, 100 lg/mL
MTT was added to cells, and cells were incubated for an
additional 4 h at 37 °C. After that, the growth medium
was removed, and 100 mL DMSO was added to each
well to ensure solubilization of formazan crystals. Finally,
the absorbance was determined using plate reader at a
wavelength of 540 nm. Each experiment was assayed
three times in triplicate. As using ‘GraphPad Prism 5’ soft-
ware program, IC50 values (the concentration of drug that
inhibits 50% of cell proliferation as compared to untreated
control) of each compound were calculated. Three inde-
pendent assays were repeated (n = 9).
For the visualization of cells treated with DOX and M-DOX-
BSA-NPs, optical microscopy was used. PC3 and A549
cells were inoculated in 96-well plates. After waiting over-
night, 1 lM free DOX and M-DOX-BSA-NPs was added
into wells and incubated for 48 h. A control group of cells
that was not treated with any of the drug formulations was
also prepared. After incubation, they were examined using
optical microscopy (Olympus-CKX41, Tokyo, Japan).
Flow cytometry analysis for apoptosis
determination
To investigate the apoptotic effects of free DOX and M-
DOX-BSA-NPs against PC3 and A549 cell lines, Annexin
V-FITC detection kit was used. Cells (1 9 105/well) were
inoculated in a 6-well plate in 1.80 mL growth medium
and incubated at 37 °C in 5% CO2 for 24 h as described
in an earlier study (11). After incubation, 20 lL of free DOX
and M-DOX-BSA-NPs, which is dissolved in PBS and
DMSO, respectively, was added, and cells were incubated
at 37 °C in 5% CO2. Final concentrations of each drug
formulation were 1–1000 nM. Untreated cells were used as
a control group. At the end of 48 h, trypsin was added to
cells and cells were centrifuged for 5 min. The pellet was
washed with PBS. After that, the pellet was resuspended
in 200 lL of binding buffer and 2 lL of annexin V-FITC,
and propidium iodide (PI) was added. The stained cells
were incubated for 15 min. at room temperature (25 °C).
Finally, the mixture was subjected to flow cytometer (Fac-
santo; Beckton Dickinson, San Jose, CA, USA) analysis.
Cell cycle analysis
To determine the cell cycle effects of the free DOX and M-
DOX-BSA-NPs against PC3 and A549 cells, these drugs
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were tested by PI staining. Cells (5 9 105/well) were inoc-
ulated in a 6-well plate in 1.80 mL growth medium and
incubated at 37 °C in 5% CO2 for 24 h. After the incuba-
tion period, 20 lL of free DOX and M-DOX-BSA-NPs dis-
solved in PBS and DMSO, respectively, at a concentration
range between 1 and 1000 nM. Cells were incubated at
37 °C in 5% CO2 for 48 h, and untreated cells were used
as a control group. Cells were then centrifuged at
280 9 g for 10 min. The supernatant was discarded, and
the pellet was used in the following steps. After washing
with PBS, the pellet was suspended in 1 mL PBS and
fixed by adding 4 mL ethanol slowly over an ice bath. The
cell suspension was centrifuged at 1200 rpm for 10 min at
4 °C. Pellet was resuspended in 200 lL of 0.1% Triton-X-
100 in PBS. RNAse A (200 lg/mL, 20 lL) was added to
cell suspension, and cells were incubated in 37 °C in 5%
CO2 for 30 min. Twenty microliter of PI (1 mg/mL) was
added and incubated at room temperature for 15 min.
The cell cycle distribution was determined by flow cytome-
ter, and data were analyzed by ModFit software.
Nanoparticles cellular uptake
Cellular uptake of M-DOX-BSA-NPs was investigated by
spin-disk confocal microscopy (Andor Technology Spin-
ning Disc Confocal Microscopy). Firstly, lamelle was placed
in a 6-well plate, and then PC3 and A549 cells were inoc-
ulated in 2 mL growth medium and allowed to adhere for
24 h. The cell growth medium was changed with 2 mL of
fresh medium containing 1 lM M-DOX-BSA-NPs. After
2 h, lamelle was carefully taken and fixed on lame. Finally,
the lame was examined using spin-disk confocal micros-
copy.
Results and Discussion
Synthesis and characterization of nanoparticles
For the nanoparticle preparation, the desolvation method
was used as it simple and the resulting particles can be
recovered easily. The obtained particles are in range of
acceptable nanometer size by this method compared to
those synthesized using the emulsion techniques (12).
In albumin nanoparticles, doxorubicin can be entrapped
via the combination of hydrophobic and ionic interactions
(between –NH3
+ of DOX and –COO of albumin) and
chemical attachment through glutaraldehyde (13). To pro-
vide magnetic targeting with nanoparticles, Fe3O4 was
added to the mixture during nanoparticle preparation. Iron
oxide MNPs, such as magnetite Fe3O4 or its oxidized and
more stable form of maghemite c-Fe2O3, are superior to
other metal oxide nanoparticles for their biocompatibility
and stability and are, by far, the most commonly employed
MNPs for biomedical applications (14).
Hydrodynamic diameter of obtained nanoparticles was
about 210 nm. AFM image of nanoparticles has revealed
to the size and spherical shape of nanoparticles. Magneti-
zation value of M-DOX-BSA-NPs was found experimentally
2.5 emu/g at room temperature when 500 G of magnetic
field was applied. XRD pattern analysis also has confirmed
Fe3O4 structure in albumin nanoparticles (5). These data
have demonstrated that M-DOX-BSA-NPs are responsive
to the magnetic field and have ideal properties as a drug
carrier.
In vitro cytotoxicity assessments
The cytotoxicity of BSA-NPs, M-BSA-NPs, DOX, DOX-
BSA-NPs, M-DOX-BSA-NPs at various concentrations
(0.02–50 lM) against PC3 and A549 cell lines was investi-
gated. It was expected that the unloaded BSA-NPs or M-
BSA-NPs would not show toxic effect on both cancer cell
lines as they are biocompatible. Viability of both cells was
approximately 100% (data not shown). Similar results were
obtained in other reports described by Li et al., Quan
et al., and Shen et al., (15–17). When DOX, DOX-BSA-
NPs, and M-DOX-BSA-NPs were applied on PC3 and
A549 cells, cell viability decreased with increasing drug
concentration. On the other hand, DOX-carrying nanopar-
ticles showed concentration-dependent inhibitory effects
on cell viability, a pattern that is similar to that of DOX
alone. The MTT test demonstrated that there was no
pharmacodynamic loss of DOX during the preparation of
M-DOX-BSA-NPs; each of M-DOX-BSA-NPs and DOX
had a significant inhibition effect against PC3 and A549
cells. IC50 values of DOX, DOX-BSA-NPs, and M-DOX-
BSA-NPs for PC3 cells were 0.51, 0.14, and 0.035 lM,
and IC50 values of DOX, DOX-BSA-NPs, and M-DOX-
BSA-NPs for A549 cells were 9.13, 3.24, and 1.68 lM,
respectively. Both DOX-BSA-NPs and M-DOX-BSA-NPs
were more effective than free DOX in PC3 and A549 cells;
however, M-DOX-BSA-NPs have more cytotoxic effect
than DOX-BSA-NPs. Our results revealed that a lower
concentration of M-DOX-BSA-NPs was needed to
decrease viability of both PC3 and A549 cells than free
DOX to induce the same effect. These findings can be
defined by the combination of cellular uptake, drug resis-
tance, and drug release in the acidic compartments. In
comparison with the cell viability of two cell lines, A549
cells showed lower sensitivity to the treatment with free
DOX or DOX-carrying nanoparticles. The lower sensitivity
to DOX treatment was ascribed to drug sequestration by
lung resistance-related protein (LRP) inside the cytoplas-
mic compartments (18). A similar result was obtained in
an other report described by Azarmi et al. (19). Cellular
uptake of nanoparticles and large molecules is generally
accepted to be by an endocytosis mechanism through
which they accumulate in the acidic compartments of
early endosomes and then trafficked to the lysosomes
(20). As we showed in the earlier study (5), DOX release
from nanoparticles in acidic medium is faster. Therefore,
we can suggest that after nanoparticles internalized into
cells, DOX released from nanoparticles in the acidic intra-
cellular organelles.
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Moreover, besides the greater cytotoxicity of M-DOX-BSA-
NPs than free DOX against cancer cells, the uptake into
solid tumors of albumin nanoparticles may be enhanced
by albondin (gp60) receptor and secreted protein, acidic,
and rich in cysteine (SPARC), resulting selective accumula-
tion (21). Albondin receptor on the endothelial cells of
tumor vessels allows transcytosis of albumin across con-
tinuous endothelium, and SPARC results in accumulation
of albumin within the tumor interstitium (2,22). In our drug
carrier system, magnetite structure could serve as an addi-
tional targeting agent to deliver the drug to a tumoral
region with the aid of external magnetic field.
To understand how these cancer cells appeared before
and after treatment with free DOX and M-DOX-BSA-NPs,
optical microscopy was used. DOX-treated cells were
damaged, and the number of whole cells was fewer, while
most of control cells were viable. After treatment with M-
DOX-BSA-NPs, almost whole cells showed characteristics
of apoptosis morphology. These images have confirmed
the MTT results.
Flow cytometry analysis for apoptosis
determination
To investigate the apoptotic effects of free DOX and M-
DOX-BSA-NPs against PC-3 and A549 cells, flow cytome-
try-based Annexin V staining was performed. The percent-
age of cell phase composition was calculated and shown
in Figures 1 and 2. When free doxorubicin at a concentra-
tion of 100 nM was applied on cells, nearly 30% of PC3
and 50% of A549 cells were counted as viable. Other
accounted cells were in necrosis, late apoptosis, or early
apoptosis phase. At the lower concentration of free DOX,
most of cells were found alive. When M-DOX-BSA-NPs at
a concentration of 10 nM were applied to cells, about 20%
of PC3 and 70% of A549 cells were determined as alive.
Both DOX and M-DOX-BSA-NPs have induced apoptotic
cell death; at higher doses, necrosis could be accounted
for cell death. The specific form of cell death resulting from
doxorubicin treatment varies depending on the concentra-
tion of the drug, treatment duration, and specific form of
cancer (23).
Briefly, a lower concentration of M-DOX-BSA-NPs was
needed to decrease viability of both PC3 and A549 cells
than free DOX to induce the same effect. These results
confirmed cell viability percentage data based on MTT
test. Flow cytometry analysis results are given in Figures 3
and 4.
Cell cycle analysis
It is known that as a result of doxorubicin action in the cell,
cellular growth is inhibited at phases G1 and G2 (23). To
investigate the cell cycle effects of free DOX and M-DOX-
BSA-NPs against PC-3 and A549 cells, DOX and this
compound were applied at the different concentrations (1,
10, 100, and 1000 nM), and untreated cells were used as
a control group, which was analyzed using flow cytometry-
based propidium iodide (PI) staining. Firstly, it was investi-
gated for doxorubicin against PC-3 cells and obtained cell
phase composition according to G2, S, and G1 phase
(Figure 5). G1 phase marks the beginning of DNA synthe-
sis, S phase is DNA replication, and G2 phase is the last
phase until the cell enters mitosis. As doxorubicin affects
DNA, an increase in G1 phase was expected when high
concentration of doxorubicin was applied. As doxorubicin
concentration was increased, G1 phase (1–1000 nM to
4.6–35.7%, respectively) was increased, but the highest
doxorubicin concentration reflected an increased number
of cells in S phase (57.2%). The percentage of cells in G1
phase was found to be similar to the control group
(40.6%). Secondly, the effect of M-DOX-BSA-NPs was
Figure 2: The phase composition percentage of A549 cells
exposed to varying concentrations of DOX and M-DOX-BSA-NPs.
Figure 1: The phase composition percentage of PC3 cells
exposed to varying concentrations of DOX and M-DOX-BSA-NPs.
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investigated (Figure 5). According to Figure 5, when con-
centration of M-DOX-BSA-NPs was increased, G1 phase
(1–1000 nM to 5.5–58.2%, respectively) was increased as
expected. On the other hand, when lower concentration of
the compound was applied, cells in G2 phase increased.
For this reason, it was thought that nanoparticles might
affect G2 phase.
Next, doxorubicin was investigated against A549 cells (Fig-
ure 6). As regards to Figure 6, the percentage of cells in
G1 phase was found to be similar to the control group
(65.8%) at all concentration. Consequently, these concen-
trations of doxorubicin against A549 cells were not enough
for increased G1 phase (1–1000 nM to 59.1–55.8%,
respectively). Finally, the effect of M-DOX-BSA-NPs was
investigated (Figure 6). The percentage of cell phase com-
position was calculated. As the concentration of M-DOX-
BSA-NPs increased, G1 phase (1–1000 nM to 48.2–
64.7%, respectively) increased as expected. However,
when lower concentrations of the compound were applied,
A B
Figure 4: Flow cytometry data for
A549 cells (A) 1 nM of DOX (B) 1 nM
of M-DOX-BSANPs.
A B
Figure 3: Flow cytometry data for
PC3 cells (A) 1 nM of DOX (B) 1 nM
of M-DOX-BSANPs.
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G2 phase (1–1000 nM to 45.7–5.3%, respectively)
increased as in PC-3 cell results. These results supported
that nanoparticles have affected G2 phase.
Nanoparticles cellular uptake
To understand the deposition place of M-DOX-BSA-NPs
in both cell types, spin-disk confocal microscopy was
used (Figure 7). As doxorubicin affects DNA, it is expected
that M-DOX-BSA-NPs may enter the nucleus. In fact, Fig-
ure 7B shows that M-DOX-BSA-NPs were in the PC3 cell
and have reached nucleus.
On the other hand, when the same method was per-
formed for A549 cells, it was observed that M-DOX-BSA-
NPs have stayed in cell membrane and could not reach
Figure 6: Effects of DOX and M-DOX-BSA-NPs with varying
concentrations on cell cycle distribution of A549 cell lines.
A B
C D
Figure 7: Spin-disk confocal
microscopy images of PC3 cells
treated with (A) PBS, (B) 1 lg/mL
of M-DOX-BSA-NPs, and A549
cells treated with (C) PBS, (D) 1 lg/
mL of M-DOXBSA-NPs.
Figure 5: Effects of DOX and M-DOX-BSA-NPs with varying
concentrations on cell cycle distribution of PC3 cell lines.
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the nucleus (Figure 7D). For this reason, it was thought
that incubation time or concentration of M-DOX-BSA-NPs
could not be enough for lung cancer cells. The image
results indicated that M-DOX-BSA-NPs were more effec-
tive on prostate cancer cells.
Conclusion
Nanoparticles made of albumin represent a promising
strategy for targeted delivery of anticancer drugs. In this
study, doxorubicin-loaded magnetic albumin nanoparti-
cles showed enhanced cytotoxic effect on both PC3
and A549 cells and nanoparticles induced more cell
death than that of free doxorubicin, as determined in an
apoptosis assay. The results indicated that with increas-
ing concentrations of both formulation and free dox, the
number of live cells is decreasing. However, it should be
said that nanoparticles drive the cells to apoptosis in a
controlled manner, and with increasing concentration,
the transition between early and late apoptosis is quite
mild. Cell cycle effects of free DOX and M-DOX-BSA-
NPs against PC-3 and A549 cells were evaluated to
determine the phase of cell cycle affected. Cell cycle
analysis on both PC3 cell line and A549 cell line showed
that doxorubicin-loaded magnetic albumin nanoparticles
affect the G2 phase of a cell cycle. This supports the
notion that these formulations affect the cell’s prepara-
tion for division. Also, confocal microscopy image results
demonstrated the uptake of magnetic nanospheres.
According to the results, we suggest that doxorubicin-
incorporated magnetic nanospheres provide many
advantages as targeted drug delivery, enhanced drug
killing ability and bioavailability. However, the advantages
of the anticancer effects of M-DOX-BSA-NPs need
in vivo further evaluation.
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